About 300 reports

  • 7.11.2 DR. REDDY'S LABORATORIES - MAJOR BIOSIMILARS APPROVED FOR MARKETING
  • The following compounds are being studied as potential biosimilars:
  • Oncology
  • World
  • Market Size
  • Amgen Inc.
  • Biocon Limited

SANDOZ EXPECTS TO TAKE MARKET SHARE FROM AMGEN' S FILGRASTIM, WHICH HELD ##% OF THE US MARKET FOUR MONTHS AFTER THE LAUNCH OF ZARXIO.

  • Biosimilar
  • Oncology
  • World
  • Market Size
  • Remicade group
  • Cancer Supportive Care Market, Global, Approved Indications for Neulasta, 2017
  • Cancer Supportive Care Market, Global, Pipeline Products, Unknown Stage of Development,
  • Oncology
  • World
  • Amgen Inc.
  • Daiichi Sankyo Company
  • Eli Lilly & Co.
  • Chemotherapy-induced neutropenia

NEUPOGEN (FILGRASTIM) Cancer pain affects a large number of individuals undergoing cancer treatment.

  • Blood Disease
  • Oncology
  • Amgen Inc.
  • Helsinn Group
  • Merck & Co., Inc.
  • Febrile Neutropenia - Dormant Projects
  • Febrile Neutropenia - Therapeutics Assessment
  • Oncology
  • Therapy
  • United States
  • World
  • Coherus BioSciences, Inc.
  • Biocon Limited - Early Stage Pipeline Products
  • Biocon Limited - Pipeline by Indication, 2016

filgrastim - Drug Profile insulin aspart - Drug Profile insulin glargine - Drug Profile Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description insulin glargine Biocon Limited NA Mylan N. V.

  • Oncology
  • India
  • World
  • Product Initiative
  • Biocon Limited
  • YPEG-FILGRASTIM - DRUG PROFILE
  • CHEMOTHERAPY INDUCED NEUTROPENIA - PIPELINE BY MYCENAX BIOTECH INC, H1 2017
  • Chemotherapy
  • Oncology
  • United States
  • Product Initiative
  • GlycoMimetics, Inc.
  • PEGFILGRASTIM - DRUG PROFILE

NA : Not Available Source: Global Markets Direct Phase II - Trial Details Other Developmental Activities FILGRASTIM - DRUG PROFILE FILGRASTIM - DRUG PROFILE FILGRASTIM - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product De

  • Biosimilar
  • Oncology
  • United States
  • Product Initiative
  • Coherus BioSciences, Inc.
  • Branded Name
  • Monoclonal Antibody
  • Oncology
  • World
  • Market Size
  • Merck & Co., Inc.
  • Financial Overview (in EUR million)

It has received approval for tbo-filgrastim (XM## filgrastim).

  • Oncology
  • Biocon Limited
  • Hospira, Inc.
  • Mylan Inc.
  • Sandoz Inc.
  • Febrile Neutropenia - Recent Pipeline Updates
  • Drug Profiles

Filgrastim works by enhancing the activity of G-CSF receptors.

  • Oncology
  • Therapy
  • United States
  • World
  • Product Initiative
  • CHEMOTHERAPY INDUCED NEUTROPENIA - PIPELINE BY BIOGENOMICS LTD
  • CHEMOTHERAPY INDUCED NEUTROPENIA - PIPELINE BY MYCENAX BIOTECH INC
  • Blood Disease
  • Oncology
  • United States
  • Product Initiative
  • Pfizer Inc.

filgrastim; methylprednisolone; peripheral blood stem cells; tacrolimus Northwestern University ## Oct 1999 ## Jul 2000 ## ## ## Phase I Study of CPX-##(CytarabineDaunorubicin) Liposome Injection in Patients with Advanced Hematologic Malignancies Multicenter Study of CPX-##(Cytarabine:Dauno

  • Cancer
  • Clinical Trial
  • Oncology
  • World
  • Product Initiative
  • Target
  • Official Title
  • Chemotherapy
  • Oncology
  • Therapy
  • World
  • Product Initiative
  • Clinical Trial profile. 153 Trial Title

filgrastim ## cyclophosphamide ## docetaxel (piperacillin sodium + tazobactam sodium) (piperacillin + tazobactam) Total Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database (*)Trials are taken for a time period of 1995 - 2017 2017 trials are taken as of August 2017 ##

  • Chemotherapy
  • Clinical Trial
  • Oncology
  • World
  • Amgen Inc.
  • 8.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS

One of the important milestones realized on this front was the FDA approval for Sandoz' s (Germany) filgrastim biosimilar-Zarxio (filgrastim-sndz)-for all five indications of the originator product-Neupogen-in 2015.

  • Oncology
  • Asia
  • Europe
  • World
  • Market Size
  • Clinical Trial profile. 43 Trial Title
  • CLINICAL TRIAL PROFILE SNAPSHOTS

filgrastim; fludarabine; melphalan Scripps Health ## Mar 2005 ## Jan 2021 ## ## ## DNA Synthesis Inhibitor DNA Clinical Trial profile. ## Trial Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Biomarker(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s

  • Leukemia
  • Oncology
  • World
  • Product Initiative
  • Alexion Pharmaceuticals, Inc.
  • Clinical Trial profile. 115 Trial Title
  • Clinical Trial profile. 51 Trial Title
  • Blood Disease
  • Oncology
  • World
  • Product Initiative
  • Amgen Inc.
  • TRASTUZUMAB BIOSIMILARS, 2017
  • shows the current status of known trastuzumab biosimilars for HER2-positive breast cancer.

The FDA requires that the biosimilar INN is followed by a four letter suffix, denoting the product manufacturer name, such as filgrastim-sndz in the case of the filgrastim TABLE ##: TRASTUZUMAB BIOSIMILARS, 2017 ##. ##. ## NOMENCLATURE biosimilar by Sandoz.

  • Oncology
  • Forecast
  • Novartis AG
  • Pfizer Inc.
  • Roche Group
  • 3. GDCT ID is the unique ID of GlobalData's Pharma Intelligence Center clinical trial database
  • Clinical Trial profile. 241 Trial Title

filgrastim; leucovorin; mesna; methotrexate; thiotepa; vincristine Nationwide Children' ' s Hospital National Cancer Institute US ## Sep 2015 ## Sep 2020 ## ## ## ##.

  • Clinical Trial
  • Oncology
  • United States
  • World
  • Product Initiative
  • CHEMOTHERAPY INDUCED NEUTROPENIA - PIPELINE BY OCTAPHARMA AG, H2 2017
  • CHEMOTHERAPY INDUCED NEUTROPENIA - PIPELINE BY MYCENAX BIOTECH INC, H2 2017
  • Chemotherapy
  • Oncology
  • United States
  • World
  • Product Initiative

Filgrastim in Treating Patients with Burkitt' s Lymphoma or Burkitt' s Leukemia GDCT## NCT##, U##CA##; CALGB-##; CDR## Oncology Burkitt Lymphoma, Leukemias, Lymphoma Completed Phase II Interventional allopurinol; cyclophosphamide; cytarabine; dexamethasone; doxoru

  • HIV AIDS
  • Lymphoma
  • Oncology
  • World
  • Product Initiative

filgrastim; sargramostim Fred Hutchinson Cancer Research Center ## Mar 1995 ## Oct 1997 ## ## Clinical Trial profile. ## Trial Title Official Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s) Collaborato

  • Biological Therapy
  • Drug Discovery And Development
  • Oncology
  • World
  • Product Initiative

Gallbladder Cancer Global Clinical Trials Review, H##, 2017 HEA LTH CA REHEA LTH CA RE REFERENCE CODE: GDHC##CTIDB PUBLICATION DATE: AUG 2017 LIST OF TABLES Gallbladder Cancer Global Clinical Trials Review, H##, 2017 outlines clinical trials in Gallbladder Cancer.

  • Cancer
  • Chemotherapy
  • Clinical Trial
  • Oncology
  • Eli Lilly & Co.

Filgrastim or Lenograstim or CSF##), Hematopoietic Progenitor Cell Antigen CD## (CD##)) Completed Phase II Interventional allogeneic bone marrow stem cells; allogeneic peripheral blood stem cells; anti-thymocyte globulin; autologous bone marrow derived stem cells; cyclophosphamide; cytarabin

  • Blood Disease
  • Leukemia
  • Oncology
  • Transplantation
  • Novartis AG
  • Nonseminomatous Testicular Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs,
  • Nonseminomatous Testicular Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent
  • Cancer
  • Chemotherapy
  • Oncology
  • World
  • Product Initiative
  • Fanconi Anemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

filgrastim ## fludarabine anti-thymocyte globulin busulfan ## ## ## plerixafor ## Total Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database (*)Trials are taken for a time period of 1995 - 2017 2017 trials are taken as of August 2017 ## CLINICAL TRIAL PROFILE SNAPSHOTS N

  • Blood Disease
  • Leukemia
  • Oncology
  • World
  • Product Initiative
  • 5. All the trials included are unique trials.

Filgrastim or Lenograstim or CSF##)) Completed Phase I Interventional busulfan; filgrastim; melphalan; peripheral blood stem cells; thiotepa Fred Hutchinson Cancer Research Center National Cancer Institute US ## Mar 1998 ## Jan 2002 ## ## ## ## A Phase I Study of the Chemoprotectant A

  • Chemotherapy
  • Oncology
  • World
  • Product Initiative
  • Eli Lilly & Co.
  • Clinical Trial profile. 153 Trial Title
  • Clinical Trial profile. 34 Trial Title
  • Cancer
  • Clinical Trial
  • Oncology
  • United States
  • World
  • TOTAL SALES AS REPORTED BY AMGEN AND KHK
  • TOTAL SALES (EX-JAPAN) AS REPORTED BY AMGEN

Neupogen (filgrastim) ##.

  • Oncology
  • Asia
  • Japan
  • Amgen Inc.
  • Kyowa Hakko Kirin Co., Ltd.